article thumbnail

Preserving Patient Access to Compounded Medications Act of 2017

Pharmacy Times

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

article thumbnail

Axcelead DDP and Astellas partner for targeted protein degrader discovery

Pharmaceutical Business Review

This collaboration aims to leverage Axcelead’s DegLead Platform, an integrated service solution designed for the next generation of small-molecule drug discovery, to support Astellas discovery efforts and contribute to the generation of drug candidate compounds.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Extemporaneous Compounding

RX Note

Introduction In 2018, the Ministry of Health Malaysia published the Good Compounding Practice as a guidance for compounding practices. NOTE: When compounding a preparation using the contents of an ampoule , care should be taken to withdraw the solution using a filter needle to avoid incorporating glass particles into the compound.

article thumbnail

Chemotherapy and Compounding – What You NEED to Know

epicur

Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. But compounding is not easy, it requires skill, training, and consistency.

article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine.

article thumbnail

The digital transformation of pharma’s physician engagement strategies

pharmaphorum

In doing so it’s compounded pre-existing pressure with pharma, where schedules are shrinking and policies are often already restrictive enough to build barriers for effective physician engagement. The threat of disease spread and other risk factors from COVID-19 have only compounded this.

article thumbnail

Rapid microbiology testing market growth expected 2022 to 2027

European Pharmaceutical Review

A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 The research includes historic market data from 2017 to 2021, using 2022 as the base year. million in 2017 and continued to grow until 2021. percent between 2022 and 2027.